Recent Patents on Light Based Therapies: Photodynamic Therapy, Photothermal Therapy and Photoimmunotherapy

ISSN: 2212-3334 (Online)
ISSN: 1872-2148 (Print)

Volume 11, 2 Issues, 2017

Download PDF Flyer

Recent Patents on Endocrine Metabolic & Immune Drug Discovery

This journal supports open access

Aims & ScopeAbstracted/Indexed in

Submit Abstracts Online Submit Manuscripts Online

View Full Editorial Board

Subscribe Purchase Articles Order Reprints

Recent Patents on Light Based Therapies: Photodynamic Therapy, Photothermal Therapy and Photoimmunotherapy

Recent Patents on Endocrine Metabolic & Immune Drug Discovery, 8(1): 1-8.

Author(s): Emilio J. Sanchez-Barcelo and Maria D Mediavilla.

Affiliation: Department of Physiology and Pharmacology,School of Medicine,University of Cantabria, 39011 Santander, Spain


This article reviews the more recent patents in three kinds of therapeutic strategies using the application of visible light to irradiate photosensible substances (PSs) of different natures. The light-activation of these PSs is directly responsible for the desired therapeutic effects. This group of light therapies includes photodynamic therapy (PDT), photothermal therapy (PTT) and photoimmunotherapy (PIT). Therapeutic mechanisms triggered by the activation of the PSs depend basically (though not exclusively) on the release of reactive oxygen species (ROS) and the activation of immune responses (PDT and PIT) or the local generation of heat (PTT). The main difference between PIT and PDT is that in PIT, monoclonal antibodies (MABs) are associated to PSs to improve the selective binding of the PSs to the target tissues. All these therapeutic strategies offer the possibility of destroying tumor tissue without damaging the surrounding healthy tissue, which is not achievable with chemotherapy or radiotherapy. PDT is also used as an alternative or adjuvant antimicrobial therapy together with the traditional antibiotic therapy since these organisms are unlikely to develop resistance to the ROS induced by PDT. Furthermore, PDT also induces an immune response against bacterial pathogens. The current challenge in PDT, PIT and PTT is to obtain the highest level of selectivity to act on targeted sick tissues with the minimum effects on the surrounding healthy tissue. The development of new PSs with high affinity for specific tissues, new PSs- MABs conjugates to bind to specific kinds of tumors, and new light-sensible nanoparticles with low toxicity, will increase the clinical utility of these therapies.


Cancer therapy, microbial infections, monoclonal antibodies (MABs), nanoparticles, nanovectors, near infrared radiation (NIR), PDT, photosensitizers, PIT, PTT, reactive oxygen species (ROS), singlet oxygen.

Download Free Order Reprints Order Eprints Rights and Permissions

Article Details

Volume: 8
Issue Number: 1
First Page: 1
Last Page: 8
Page Count: 8
DOI: 10.2174/1872214807666131229103707

Related Journals

Webmaster Contact: Copyright © 2016 Bentham Science